Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that
Dr. Rob Koremans, has been appointed President and CEO, Teva Europe and
will join the company in March 2012. Dr. Koremans joins Teva after
serving as CEO for Zentiva and most recently Senior Vice President
Generic Strategy and Development at Sanofi-Aventis.
After six intensive years, Dr. Gerard van Odijk, Teva Europe's current
President and CEO has decided to step down.
In the next few months, Dr. Koremans and Dr. van Odijk will work closely
together to ensure a smooth transition. Dr. van Odijk will remain with
Teva to support the EU region for the remainder of 2012.
Shlomo Yanai, President and CEO of Teva Pharmaceutical Industries, said,
"I would like to express my personal and profound thanks to Gerard van
Odijk for his leadership of Teva in Europe. Under his management, our
business in Europe has been transformed as Teva became the undisputed
generics leader in this major and growing market and established a
strong position in specialty pharmaceuticals. I respect Gerard's
decision to step down and spend more time with his family, and I wish
him a lot of success in the future. I am very confident that Rob
Koremans, together with our strong European management, will continue
our success story across Europe".
Dr. Rob Koremans (49) holds a medical degree from Erasmus University of
Rotterdam, Netherlands. He began his career in 1988 at Sanofi SA. In
1993 he joined the Serono Group and was appointed Vice-President, Europe
in 1998; from 2007 to 2009, Rob was Chief Executive Officer of
Cryo-Save, Europe's leading Stem Cell Storage Company. He returned to
Sanofi in 2009 as Senior Vice President, Generics Europe,
Sanofi-Aventis, and CEO of Zentiva. He was appointed President of
Zentiva in July 2010 and later became Sanofi's Senior Vice President
Generic Strategy and Development.
About Teva
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic
drugs as well as innovative and specialty pharmaceuticals and active
pharmaceutical ingredients. Headquartered in Israel, Teva is the world's
largest generic drug maker, with a global product portfolio of more than
1,300 molecules and a direct presence in about 60 countries. Teva's
branded businesses focus on CNS, oncology, pain, respiratory and women's
health therapeutic areas as well as biologics.